TWI781651B - 酞嗪酮類化合物及其製備方法和醫藥用途 - Google Patents

酞嗪酮類化合物及其製備方法和醫藥用途 Download PDF

Info

Publication number
TWI781651B
TWI781651B TW110121476A TW110121476A TWI781651B TW I781651 B TWI781651 B TW I781651B TW 110121476 A TW110121476 A TW 110121476A TW 110121476 A TW110121476 A TW 110121476A TW I781651 B TWI781651 B TW I781651B
Authority
TW
Taiwan
Prior art keywords
alkyl
mmol
optionally substituted
room temperature
compound
Prior art date
Application number
TW110121476A
Other languages
English (en)
Chinese (zh)
Other versions
TW202146400A (zh
Inventor
陸洪福
邢唯強
呂永聰
齊保建
彭建彪
海兵 郭
Original Assignee
大陸商上海濟煜醫藥科技有限公司
大陸商江西濟民可信集團有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商上海濟煜醫藥科技有限公司, 大陸商江西濟民可信集團有限公司 filed Critical 大陸商上海濟煜醫藥科技有限公司
Publication of TW202146400A publication Critical patent/TW202146400A/zh
Application granted granted Critical
Publication of TWI781651B publication Critical patent/TWI781651B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW110121476A 2020-06-12 2021-06-11 酞嗪酮類化合物及其製備方法和醫藥用途 TWI781651B (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
CN202010536221 2020-06-12
CN202010536221.6 2020-06-12
CN202011147078.8 2020-10-23
CN202011147078 2020-10-23
CN202011261665 2020-11-12
CN202011261665.X 2020-11-12
CN202110485680 2021-04-30
CN202110485680.0 2021-04-30
CN202110614030.1 2021-06-02
CN202110614030 2021-06-02

Publications (2)

Publication Number Publication Date
TW202146400A TW202146400A (zh) 2021-12-16
TWI781651B true TWI781651B (zh) 2022-10-21

Family

ID=78846889

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110121476A TWI781651B (zh) 2020-06-12 2021-06-11 酞嗪酮類化合物及其製備方法和醫藥用途

Country Status (18)

Country Link
US (3) US20230131252A1 (cg-RX-API-DMAC7.html)
EP (1) EP4166550A4 (cg-RX-API-DMAC7.html)
JP (2) JP7797421B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230024328A (cg-RX-API-DMAC7.html)
CN (2) CN113801098B (cg-RX-API-DMAC7.html)
AU (1) AU2021286738A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022025057A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186981A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003472A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022017802A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230007A (cg-RX-API-DMAC7.html)
IL (1) IL298962A (cg-RX-API-DMAC7.html)
MX (1) MX2022015562A (cg-RX-API-DMAC7.html)
PE (1) PE20230610A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023550018A1 (cg-RX-API-DMAC7.html)
SA (1) SA522441725B1 (cg-RX-API-DMAC7.html)
TW (1) TWI781651B (cg-RX-API-DMAC7.html)
WO (1) WO2021249534A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021127443A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
AU2020414151A1 (en) 2019-12-23 2022-08-25 Jiangxi Jemincare Group Co., Ltd Protein degradation agent compound preparation method and application
CA3174353A1 (en) * 2020-04-08 2021-10-14 Dominic Reynolds Compounds and methods for modulating splicing
CN115996918A (zh) 2020-05-09 2023-04-21 阿尔维纳斯运营股份有限公司 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
KR20230024328A (ko) 2020-06-12 2023-02-20 상하이 제민케어 파마슈티칼스 컴퍼니 리미티드 프탈라지논 화합물, 이의 제조 방법 및 이의 의학적 용도
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
KR102474999B1 (ko) * 2021-05-26 2022-12-07 주식회사 이노큐어테라퓨틱스 피페리딘디온 유도체
JP2024519628A (ja) * 2021-05-26 2024-05-21 イノキュア セラピューティクス インコーポレイテッド ピペリジンジオン誘導体
WO2023016518A1 (zh) 2021-08-11 2023-02-16 四川海思科制药有限公司 一种杂环衍生物及其组合物和药学上的应用
US20260159520A1 (en) * 2022-09-08 2026-06-11 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2024054952A1 (en) * 2022-09-08 2024-03-14 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
JP2025538554A (ja) * 2022-11-22 2025-11-28 イノキュア セラピューティクス,インコーポレイテッド Brdタンパク質を分解するための分解剤およびそれを含有する薬学的組成物
EP4624472A1 (en) * 2022-11-22 2025-10-01 Innocure Therapeutics, Inc. Degrader including novel c-met protein ligand and pharmaceutical composition including same
EP4624466A1 (en) * 2022-11-22 2025-10-01 Innocure Therapeutics, Inc. Degrader for decomposing cmet protein, and pharmaceutical composition comprising same
CN116655591B (zh) * 2023-06-05 2024-11-08 中国人民解放军军事科学院军事医学研究院 3,4-二氢酞嗪-1(2h)-酮类衍生物及制备方法和用途
EP4763845A1 (en) 2023-08-17 2026-06-24 Haisco Pharmaceutical Group Co., Ltd. Cyano aromatic ring derivative and pharmaceutical use thereof
EP4780815A1 (en) 2023-09-20 2026-07-29 Aurigene Oncology Limited Heterocyclic compounds as cbp selective degraders
WO2025085738A1 (en) 2023-10-18 2025-04-24 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2025108406A1 (zh) * 2023-11-22 2025-05-30 广东东阳光药业股份有限公司 一种靶向降解雄激素受体的双功能嵌合体的杂环化合物及其用途
AU2024392985A1 (en) 2023-12-08 2026-06-04 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy
WO2025189056A1 (en) 2024-03-08 2025-09-12 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and their use in treating disease
TW202600539A (zh) 2024-03-13 2026-01-01 美商建南德克公司 Ar降解劑之多形體
WO2025193851A1 (en) 2024-03-13 2025-09-18 Genentech, Inc. Process for making enantiomers of ar-degraders
WO2025226797A1 (en) 2024-04-24 2025-10-30 Genentech, Inc. Kred catalyzed ketoreduction of a cyclobutanone carbamic ester
US12169941B1 (en) 2024-06-13 2024-12-17 Rapsodo Pte. Ltd. System and method for determining a position an object crosses a target plane

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110612294A (zh) * 2017-01-31 2019-12-24 阿尔维纳斯运营股份有限公司 人小脑蛋白配体和包含其的双官能化合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245804B1 (en) * 1997-05-30 2001-06-12 Schering Aktiengesellschaft Nonsteroidal gestagens
DE19723722A1 (de) * 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
EP4649963A3 (en) 2014-04-14 2026-05-13 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
JP6817962B2 (ja) * 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. ターゲティングされたアンドロゲン受容体分解のための化合物および方法
CA2988414C (en) 2015-06-04 2023-09-26 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
SI3526202T1 (sl) * 2016-10-11 2025-04-30 Arvinas Operations, Inc. Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
US10842878B2 (en) 2016-11-22 2020-11-24 Dana-Farber Cancer Institute, Inc. Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
AU2017363257B2 (en) 2016-11-22 2021-08-19 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
CN110194762B (zh) * 2018-02-27 2021-09-10 中国科学院上海药物研究所 酞嗪酮类衍生物、其制备方法和用途
CN112390852B (zh) 2019-08-14 2022-10-18 上海济煜医药科技有限公司 作为蛋白降解剂的化合物及其制备方法和应用
CN112457367B (zh) 2019-09-06 2022-08-23 上海济煜医药科技有限公司 作为蛋白降解剂的连环类化合物及其制备方法和应用
CN118085015A (zh) 2019-09-06 2024-05-28 江西济民可信集团有限公司 作为蛋白降解剂的并环类化合物及其制备方法和用途
CN112574278B (zh) 2019-09-29 2024-08-23 江西济民可信集团有限公司 作为蛋白降解剂杂环类化合物及其制备方法和医药应用
AU2020414151A1 (en) 2019-12-23 2022-08-25 Jiangxi Jemincare Group Co., Ltd Protein degradation agent compound preparation method and application
CN113582974B (zh) 2020-04-30 2022-05-17 江西济民可信集团有限公司 一类作为蛋白降解剂的化合物及其制备方法和医药用途
KR20230024328A (ko) 2020-06-12 2023-02-20 상하이 제민케어 파마슈티칼스 컴퍼니 리미티드 프탈라지논 화합물, 이의 제조 방법 및 이의 의학적 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110612294A (zh) * 2017-01-31 2019-12-24 阿尔维纳斯运营股份有限公司 人小脑蛋白配体和包含其的双官能化合物

Also Published As

Publication number Publication date
MX2022015562A (es) 2023-01-30
SA522441725B1 (ar) 2024-08-11
CA3186981A1 (en) 2021-12-16
CN116082311B (zh) 2025-04-25
BR112022025057A2 (pt) 2023-01-31
IL298962A (en) 2023-02-01
CN113801098B (zh) 2023-05-30
PE20230610A1 (es) 2023-04-13
CO2022017802A2 (es) 2023-03-17
US12234223B2 (en) 2025-02-25
PH12023550018A1 (en) 2024-03-11
JP7797421B2 (ja) 2026-01-13
JP2023531390A (ja) 2023-07-24
US11767312B2 (en) 2023-09-26
TW202146400A (zh) 2021-12-16
CL2022003472A1 (es) 2023-06-02
EP4166550A1 (en) 2023-04-19
KR20230024328A (ko) 2023-02-20
US20230242510A1 (en) 2023-08-03
JP2026053536A (ja) 2026-03-25
EP4166550A4 (en) 2024-08-07
CR20230007A (es) 2023-06-01
WO2021249534A1 (zh) 2021-12-16
US20240400540A1 (en) 2024-12-05
AU2021286738A1 (en) 2023-01-19
US20230131252A1 (en) 2023-04-27
CN116082311A (zh) 2023-05-09
CN113801098A (zh) 2021-12-17

Similar Documents

Publication Publication Date Title
CN116082311B (zh) 酞嗪酮类化合物及其制备方法和医药用途
TWI755992B (zh) 一種蛋白降解劑化合物的製備方法和應用
TWI846774B (zh) 作為免疫調節的芳環衍生物及其製備方法和應用
CN113582974B (zh) 一类作为蛋白降解剂的化合物及其制备方法和医药用途
CN112457366B (zh) 作为蛋白降解剂的并环类化合物及其制备方法和应用
CN112574278A (zh) 作为蛋白降解剂杂环类化合物及其制备方法和医药应用
WO2023143147A1 (zh) 一种哒嗪并吡啶酮类化合物、其药物组合物及应用
WO2024006776A1 (en) Estrogen receptor alpha degraders and medical use thereof
CN112457367B (zh) 作为蛋白降解剂的连环类化合物及其制备方法和应用
CN109689656A (zh) 7-取代的1-芳基二氮杂萘-3-羧酰胺及其用途
TW202540127A (zh) 一種吡咯[2,3-b]并吡啶衍生物及其製備方法和用途
TWI804119B (zh) 三氮唑類三并環衍生物及其製備方法和應用
RU2844016C1 (ru) Фталазиноновое соединение, способ его получения и его медицинское применение
CN111630029B (zh) 作为免疫调节剂的化合物及其制备方法和应用
HK40092053A (en) Phthalazinone compound, and preparation method therefor and medical use thereof
HK40104808A (en) Fused ring compound as protein degradation agent as well as preparation method and use thereof
HK40114563A (en) Heterocyclic compound as protein degradation agent as well as preparation method and medical application thereof
HK40054345B (en) Estrogen receptor antagonist

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent